$11.64
Live
0.6%
Downside
Day's Volatility :2.45%
Upside
1.85%
29.17%
Downside
52 Weeks Volatility :36.84%
Upside
10.84%
Period | Roivant Sciences Ltd. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 7.1% | 3.6% | 0.0% |
6 Months | 12.45% | 10.2% | 0.0% |
1 Year | 38.69% | 19.6% | 0.0% |
3 Years | 94.77% | 16.8% | -23.0% |
Market Capitalization | 8.8B |
Book Value | $7.35 |
Earnings Per Share (EPS) | 5.73 |
PE Ratio | 2.08 |
Wall Street Target Price | 17.06 |
Profit Margin | 2991.76% |
Operating Margin TTM | -402.44% |
Return On Assets TTM | -15.03% |
Return On Equity TTM | 127.71% |
Revenue TTM | 158.3M |
Revenue Per Share TTM | 0.2 |
Quarterly Revenue Growth YOY | 155.0% |
Gross Profit TTM | -477.1M |
EBITDA | -1.0B |
Diluted Eps TTM | 5.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 4.27 |
EPS Estimate Next Year | -1.35 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.27 |
What analysts predicted
Upside of 46.56%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.3M | - |
Net Income | -1.0B | - |
Net Profit Margin | -44.8K% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 67.7M | ↑ 2812.61% |
Net Income | 1.2B | ↓ 215.22% |
Net Profit Margin | 1.8K% | ↑ 46608.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 23.8M | ↓ 64.85% |
Net Income | -900.2M | ↓ 174.99% |
Net Profit Margin | -3.8K% | ↓ 5556.86% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 55.3M | ↑ 132.34% |
Net Income | -924.1M | ↑ 2.65% |
Net Profit Margin | -1.7K% | ↑ 2111.77% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 61.3M | ↑ 10.84% |
Net Income | -1.2B | ↑ 33.1% |
Net Profit Margin | -2.0K% | ↓ 335.7% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 124.8M | ↑ 103.65% |
Net Income | 4.3B | ↓ 453.56% |
Net Profit Margin | 3.5K% | ↑ 5492.08% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 27.4M | ↑ 60.54% |
Net Income | -175.4M | ↓ 54.42% |
Net Profit Margin | -640.79% | ↑ 1616.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.6M | ↓ 21.01% |
Net Income | -291.8M | ↑ 66.35% |
Net Profit Margin | -1.3K% | ↓ 708.71% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.1M | ↑ 71.57% |
Net Income | -304.3M | ↑ 4.29% |
Net Profit Margin | -820.27% | ↑ 529.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.1M | ↑ 0.11% |
Net Income | 5.1B | ↓ 1774.58% |
Net Profit Margin | 13.7K% | ↑ 14541.82% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 28.9M | ↓ 22.11% |
Net Income | -151.1M | ↓ 102.97% |
Net Profit Margin | -522.35% | ↓ 14243.9% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 55.1M | ↑ 90.57% |
Net Income | 95.3M | ↓ 163.06% |
Net Profit Margin | 172.85% | ↑ 695.2% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | - |
Total Liabilities | 450.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 78.49% |
Total Liabilities | 368.4M | ↓ 18.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↑ 4.55% |
Total Liabilities | 527.7M | ↑ 43.25% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↓ 0.18% |
Total Liabilities | 546.2M | ↑ 3.51% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↓ 7.56% |
Total Liabilities | 782.0M | ↑ 43.18% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 7.2B | ↑ 202.25% |
Total Liabilities | 774.0M | ↓ 1.03% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | ↑ 8.47% |
Total Liabilities | 782.0M | ↑ 0.8% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↓ 10.59% |
Total Liabilities | 802.5M | ↑ 2.62% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↓ 3.33% |
Total Liabilities | 739.9M | ↓ 7.8% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.3B | ↑ 254.03% |
Total Liabilities | 728.1M | ↓ 1.6% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 7.2B | ↓ 1.23% |
Total Liabilities | 774.0M | ↑ 6.3% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | ↓ 10.05% |
Total Liabilities | 601.2M | ↓ 22.33% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.0B | - |
Investing Cash Flow | -57.6M | - |
Financing Cash Flow | 767.0M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -761.8M | ↓ 25.62% |
Investing Cash Flow | 1.7B | ↓ 3041.94% |
Financing Cash Flow | 217.2M | ↓ 71.69% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -552.1M | ↓ 27.52% |
Investing Cash Flow | -31.7M | ↓ 101.87% |
Financing Cash Flow | 456.3M | ↑ 110.1% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -677.7M | ↑ 22.75% |
Investing Cash Flow | 303.3M | ↓ 1056.71% |
Financing Cash Flow | 306.8M | ↓ 32.76% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -843.4M | ↑ 24.44% |
Investing Cash Flow | -44.3M | ↓ 114.6% |
Financing Cash Flow | 499.5M | ↑ 62.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -179.1M | ↓ 19.54% |
Investing Cash Flow | 113.6M | ↓ 3334.21% |
Financing Cash Flow | 210.3M | ↑ 36.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -249.9M | ↑ 39.56% |
Investing Cash Flow | 105.0K | ↓ 99.91% |
Financing Cash Flow | 7.5M | ↓ 96.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -196.4M | ↓ 21.41% |
Investing Cash Flow | -36.5M | ↓ 34815.24% |
Financing Cash Flow | 207.9M | ↑ 2680.15% |
Sell
Neutral
Buy
Roivant Sciences Ltd. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Roivant Sciences Ltd. | 0.17% | 12.45% | 38.69% | 94.77% | 27.49% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Roivant Sciences Ltd. | 2.08 | 2.08 | NA | 4.27 | 1.28 | -0.15 | NA | 7.35 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Roivant Sciences Ltd. | Buy | $8.8B | 27.49% | 2.08 | 2991.76% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Roivant Sciences Ltd.
Revenue is up for the last 2 quarters, 28.93M → 55.13M (in $), with an average increase of 47.5% per quarter
Netprofit is up for the last 2 quarters, -151.11M → 95.29M (in $), with an average increase of 258.6% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 59.5%
SB INVESTMENT ADVISERS (UK) LTD
Viking Global Investors LP
Qvt Financial LP
FMR Inc
BlackRock Inc
Morgan Stanley - Brokerage Accounts
roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak
Organization | Roivant Sciences Ltd. |
Employees | 908 |
CEO | Mr. Matthew Gline |
Industry | Financial |